Accelerate to discover

Back to filter

Related topics

Squaraine fluorophore as a NIR-fluorescent probe for the in vivo detection of diagnostic enzymes

Spectral Instruments Imaging

Nov 19, 2018

An oligo(ethylene glycol)-functionalized squaraine fluorophore has been developed as an NIR-fluorescent probe that can...

IncuCyte neuronal activity assay

Sartorius

Nov 13, 2018

The generation and maturation of neuronal networks are necessary characteristics of neurogenesis, providing...

The most advanced software for preclinical imaging research

Bruker Biospin

Nov 7, 2018

Modern imaging laboratories hosting PET/MR instruments profit from the fully integrated common imaging platform...

IZON qEV - Isolate your exosomes in just 15 minutes

IZON

Oct 25, 2018

Extracellular  vesicles  (EVs)  are  prevalent  in biological  fluids  and  are  of  great  interest  to researchers ...

Nov 19, 2018

COY - personalized hypoxic chambers

COY laboratory products

Oct 18, 2018

When your research requires consistent atmospheric control to maintain hypoxia, normoxia, or hyperoxia, you can count...

Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs

Fluxion Biosciences

Oct 12, 2018

Drug delivery by nanocarriers (NCs) has long been stymied by dominant liver uptake and limited target organ deposition,...

Target large genomic regions with 10x genomics + SageHLS

Sage Science

Oct 9, 2018

With customized Cas9 nucleases, scientists can now isolate specific large genomic DNA fragments with the SageHLS...

Nov 19, 2018

Coy anaerobic chambers #1 choice in microbiology

COY laboratory products

Oct 5, 2018

Used for over 40 years in anaerobic microbiology research, COY chambers are also critical to many other research areas...

Show all topics (10)

Digital measurement for HER2 amplifcation in HER2 equivocal breast cancer diagnosis

Sep 20, 2017

Currently, there are no recommended alternative assays for HER2 cases deemed equivocal by immunohistochemistry and fuorescent in situ hybridization. Digital PCR (ddPCR), a highly accurate method to determine DNA copy number, could be a robust alternative for clinical HER2 diagnostics. HER2 and CEP17 copy numbers were quantifed using two ddPCR platforms (QX200 and RainDrop) in 102 samples of invasive breast cancers. Compared to routine assays, ddPCR gave a sensitivity
and specifcity of 82.8% and 97.3% respectively, with a kappa value of 0.833 (p<0.001). Moreover, the method proved to be robust as the results from two platforms was highly correlated R2=0.91; Concordance rate=97%; κ=0.923, P<0.001). Its performance was further tested on 114 HER2 equivocal cases in an independent validation cohort. 75% (21/28) of cases with HER2 amplifcation and 95% (82/86) of HER2 non-amplifed case were classifed as positive and negative by ddPCR respectively (κ=0.709, P<0.001). Notably, in the HER2 amplifed cases, a lower percentage of HER2 positive cells could be related to the discordant results. Altogether, ddPCR is a robust alternative for clinical HER2 diagnostics. However, intratumoral heterogeneity of HER2 status still pose a challenge for HER2 analysis by ddPCR.

Read more

Scientific paper
Application

Related technologies: Digital PCR

Get more info

Regina Fillerová

Field application specialist

Regina

Fillerová

+420 731 127 718

Send Message

Brand profile

RainDance Technologies

RainDance company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases.

Related products

Capable of generating more than a billion reactions in a single day, the RainDrop system surpasses all existing technologies and establishes a new performance standard in sensitivity, quantitation and multiplexing.

show detail

A fast, accurate and low-cost NGS target enrichment system that features award-winning instrumentation and pre-validated gene panels, as well as flexible open source options.

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey